Human Organoids

Human Organoids


Global Human Organoids Market to Reach US$4.6 Billion by 2030

The global market for Human Organoids estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 15.5% over the analysis period 2023-2030. Kidney Organoids, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Liver Organoids segment is estimated at 16.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$453.9 Million While China is Forecast to Grow at 20.7% CAGR

The Human Organoids market in the U.S. is estimated at US$453.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 20.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Human Organoids Market - Key Drivers and Trends Summarized

Human organoids are three-dimensional, miniaturized, and simplified versions of human organs that are grown in vitro from stem cells. These organoids mimic the structure and function of real organs, providing a more accurate model for studying human biology and disease. They can be developed from various types of stem cells, including induced pluripotent stem cells (iPSCs) and adult stem cells, and are capable of self-organizing into organ-specific cell types. Human organoids have been created for numerous organs, including the brain, liver, kidneys, and intestines, offering a revolutionary tool for biomedical research, drug development, and personalized medicine.

The application of human organoids has significantly advanced our understanding of human development and disease mechanisms. Researchers utilize organoids to study organogenesis, model genetic disorders, and investigate the effects of various treatments in a controlled environment that closely resembles the human body. This has led to breakthroughs in identifying new drug targets and understanding the pathology of complex diseases, such as cancer, neurodegenerative disorders, and infectious diseases. Moreover, human organoids have emerged as valuable tools in regenerative medicine, where they are used to explore potential therapies for organ repair and replacement. The development of organoid technology has been accelerated by innovations in stem cell research, bioengineering, and 3D culture techniques, resulting in more sophisticated and functional models.

The growth in the human organoids market is driven by several factors. Firstly, the increasing prevalence of chronic diseases and the need for effective treatments have spurred demand for advanced research models that can accurately mimic human physiology. Secondly, advancements in stem cell technology and 3D bioprinting have facilitated the development of more complex and functional organoids. Additionally, the push for personalized medicine has boosted the adoption of organoids, as they can be derived from individual patients` cells to tailor treatments. The rising investment in biotechnology and pharmaceutical research has further propelled market growth, with substantial funding directed towards organoid research and development. Furthermore, regulatory support and collaboration between academic institutions and industry players have accelerated the commercialization of organoid-based applications. Lastly, ethical considerations favoring the use of organoids over animal models have also contributed to the market`s expansion, as they offer a more humane and potentially more accurate alternative for preclinical testing.

Select Competitors (Total 38 Featured) -
  • BioIVT, LLC
  • Cellaïon SA
  • CN Bio Innovations Ltd
  • Corning Incorporated
  • CYPRIO
  • InSphero AG
  • KaLy-Cell
  • Kirkstall Ltd.
  • MIMETAS
  • Organovo Holdings, Inc.
  • PRIMACYT Cell Culture Technology GmbH
  • Stemcell Technologies Canada, Inc.
  • Thermo Fisher Scientific Inc.
  • Visikol, Inc.
  • WEPREDIC Group
  • ZenBio, Inc;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Human Organoids - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Personalized Medicine Drives Market Growth for Human Organoids
Advancements in Stem Cell Research Enhance Development and Applications of Organoids
Increasing Use of Organoids in Drug Discovery and Development Boosts Market
Growing Adoption of Organoids in Disease Modeling Expands Research Opportunities
Expansion of 3D Bioprinting Technologies Enhances Organoid Production
Growing Interest in Organoids for Toxicology Testing and Safety Assessment
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Human Organoids Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Human Organoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Kidney by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Lungs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Lungs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Lungs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Pancreas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Organ Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Organ Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Organ Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Regenerative Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Regenerative Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Developmental Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Developmental Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Developmental Biology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Drug Toxicity & Efficacy Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Drug Toxicity & Efficacy Testing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Drug Toxicity & Efficacy Testing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Disease Pathology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 30: World Historic Review for Disease Pathology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: World 16-Year Perspective for Disease Pathology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: World Historic Review for Personalized Medicine Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: World 16-Year Perspective for Personalized Medicine Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 36: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 39: World Historic Review for Clinical Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: World 16-Year Perspective for Clinical Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 42: World Historic Review for Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: World 16-Year Perspective for Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 44: USA Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: USA Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: USA 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: USA Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: USA 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Canada 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Canada 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
JAPAN
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Japan 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Japan 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
CHINA
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 71: China Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: China Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: China 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: China Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: China 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
EUROPE
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 80: Europe Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Human Organoids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Europe 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Europe 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
FRANCE
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 92: France Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: France Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: France 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: France Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: France 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
GERMANY
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 101: Germany Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Germany 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Germany 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
ITALY
TABLE 110: Italy Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: Italy 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Italy 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
UNITED KINGDOM
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 119: UK Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: UK Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: UK 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: UK Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: UK 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
SPAIN
TABLE 128: Spain Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: Spain 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 131: Spain Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Spain Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Spain 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 134: Spain Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Spain Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Spain 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
RUSSIA
TABLE 137: Russia Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Russia 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 140: Russia Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Russia Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Russia 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 143: Russia Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Russia Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Russia 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of Europe 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Rest of Europe Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Rest of Europe 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of Europe Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of Europe 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Human Organoids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 162: Asia-Pacific Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Asia-Pacific 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: Asia-Pacific Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: Asia-Pacific 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
AUSTRALIA
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 167: Australia Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: Australia 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 170: Australia Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 171: Australia Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: Australia 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 173: Australia Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: Australia Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: Australia 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
INDIA
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 176: India Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: India Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: India 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 179: India Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: India Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: India 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 182: India Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: India Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: India 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 185: South Korea Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: South Korea 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 188: South Korea Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: South Korea Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: South Korea 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 191: South Korea Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 192: South Korea Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: South Korea 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: Rest of Asia-Pacific Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: Rest of Asia-Pacific Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
LATIN AMERICA
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 203: Latin America Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Human Organoids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: Latin America 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 209: Latin America Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 210: Latin America Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 211: Latin America 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 212: Latin America Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 213: Latin America Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 214: Latin America 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 215: Argentina Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 217: Argentina 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 218: Argentina Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 219: Argentina Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 220: Argentina 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 221: Argentina Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 222: Argentina Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 223: Argentina 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
BRAZIL
TABLE 224: Brazil Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 226: Brazil 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 227: Brazil Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 228: Brazil Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 229: Brazil 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 230: Brazil Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 231: Brazil Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 232: Brazil 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
MEXICO
TABLE 233: Mexico Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 235: Mexico 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 236: Mexico Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 237: Mexico Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 238: Mexico 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 239: Mexico Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 240: Mexico Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 241: Mexico 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 244: Rest of Latin America 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 246: Rest of Latin America Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 247: Rest of Latin America 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 249: Rest of Latin America Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 250: Rest of Latin America 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
MIDDLE EAST
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 251: Middle East Recent Past, Current & Future Analysis for Human Organoids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Human Organoids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 253: Middle East 16-Year Perspective for Human Organoids by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 257: Middle East Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 258: Middle East Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 259: Middle East 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 260: Middle East Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 261: Middle East Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 262: Middle East 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
IRAN
TABLE 263: Iran Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 265: Iran 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 266: Iran Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 267: Iran Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 268: Iran 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 269: Iran Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 270: Iran Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 271: Iran 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
ISRAEL
TABLE 272: Israel Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 274: Israel 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 275: Israel Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 276: Israel Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 277: Israel 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 278: Israel Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 279: Israel Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 280: Israel 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 283: Saudi Arabia 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 285: Saudi Arabia Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 286: Saudi Arabia 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 288: Saudi Arabia Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 289: Saudi Arabia 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 290: UAE Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 292: UAE 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 293: UAE Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 294: UAE Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 295: UAE 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 296: UAE Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 297: UAE Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 298: UAE 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 301: Rest of Middle East 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 303: Rest of Middle East Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 304: Rest of Middle East 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 306: Rest of Middle East Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 307: Rest of Middle East 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
AFRICA
Human Organoids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 308: Africa Recent Past, Current & Future Analysis for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Human Organoids by Organ Type - Kidney, Liver, Lungs, Pancreas and Other Organ Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 310: Africa 16-Year Perspective for Human Organoids by Organ Type - Percentage Breakdown of Value Sales for Kidney, Liver, Lungs, Pancreas and Other Organ Types for the Years 2014, 2024 & 2030
TABLE 311: Africa Recent Past, Current & Future Analysis for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 312: Africa Historic Review for Human Organoids by Application - Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 313: Africa 16-Year Perspective for Human Organoids by Application - Percentage Breakdown of Value Sales for Regenerative Medicine Application, Developmental Biology Application, Drug Toxicity & Efficacy Testing Application, Disease Pathology Application and Personalized Medicine Application for the Years 2014, 2024 & 2030
TABLE 314: Africa Recent Past, Current & Future Analysis for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 315: Africa Historic Review for Human Organoids by End-Use - Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 316: Africa 16-Year Perspective for Human Organoids by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Clinical Research Organizations End-Use and Academic Institutes End-Use for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings